Request Sample
Request Methodology
Description
Emergency Contraceptives Market size was valued at USD x billion in 2021, growing at a CAGR of 3.3% from 2022 to 2028. Emergency Contraceptives Market, provides emergency contraception methods are intended to prevent unwanted pregnancies after sexual intercourse. The commonly used emergency contraceptives are pills and copper-bearing intrauterine devices. Within emergency contraceptive pills are available in 3 compositions namely, combined estrogen and progestin pills, progestin-only (as Levonorgestrel) pills, and antiprogestin (as mifepristone) pills. Emergency contraceptives are different from normal contraceptives. The mechanism of action of the emergency contraceptive methods is delaying or preventing ovulation or fertilization, which is necessary during pregnancy. Both the methods are effective only before the pregnancy testing implanted. These procedures are ineffective after the implantation occurred. Furthermore, low cost of the products, rise in the adoption of modern emergency contraceptives in developing countries, ease of administration of emergency contraceptive pills, and high effectiveness and convenience in emergency contraceptive devices might boost the global emergency contraceptives pills market. However, adverse effects like nausea, headache associated with the emergency contraceptive pills, lack of skilled professionals for the insertion of intrauterine devices, and product failures in some cases might hamper the market. Market players investing heavily to manufacture emergency contraceptives to increase their share in the market. Launching of new products, collaborations, acquisitions and mergers, approvals as over the counter (OTC) product from various drug regulators such as U.S. Food and Drug Administration, and research and developments are some key strategies followed by various pharmaceutical companies to increase the share in the global emergency contraceptives market.
Key Developments:
In August 2010, U.S. Food and Drug Administration approved the Ella (Ulipristal acetate pills) as emergency contraceptive pills which are developed by HRA pharmaceuticals.
In February 2011, Teva Pharmaceuticals received an approval from the FDA for requesting non-prescription status for Plan B One-Step for women under the age of 17.
